EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The Promising Role of Selected Fibroblast Growth Factors as Potential Markers of Complications in Type 1 and Type 2 Diabetes

Elżbieta Cecerska-Heryć iD, Jaśmina Michałów, Weronika Engwert, Julia Marciniak, Radosław Birger iD, Natalia Serwin iD, Rafał Heryć, Aleksandra Polikowska, Małgorzata Goszka, Magda Wiśniewska, Barbara Dołęgowska iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26178754 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Elżbieta Cecerska-Heryć und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Pomeranian Medical University of Szczecin, Powstancow Wielkopolskich 72, 70-111 Szczecin, Poland. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Fibroblast Growth Factors, Diabetes Mellitus, Type 1, Diabetes Complications. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pomeranian Medical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetes is a common chronic disease. Untreated diabetes may lead to complications such as nephropathy, neuropathy, retinopathy, and macroangiopathies. The main goal in treating diabetes is to limit the development of vascular complications. The FGF (fibroblast growth factor) family, with its potential as a biomarker for diabetic complications, offers a promising avenue for future research and treatment. The study aimed to analyze and compare the concentrations of selected fibroblast growth factors, FGF-2, FGF-19, FGF-22, and FGF-23, in the plasma of patients with type 1 and type 2 diabetes with those of the control group. The study group consisted of 73 patients, including 33 people with type 1 diabetes (18 M and 15 W) aged 18 to 68 years and 40 with type 2 diabetes (20 M and 20 W) aged 25 to 90. The control group consisted of 41 healthy individuals (23 men and 18 women) aged 21 to 56. The FGF-2, FGF-19, FGF-22, and FGF-23 concentrations were measured using ELISA. The study observed a significant relationship between the levels of FGF19 and FGF22 in the serum of patients with type 1 and type 2 diabetes, as well as in the control group (p < 0.001; p < 0.001). Statistical analysis revealed a significant relationship between FGF-2 and FGF-22 concentrations and hypertension (p = 0.03; p = 0.01). A statistically significant difference was also found between the concentrations of FGF-19 and FGF-22 (p = 0.001; p < 0.001) in the serum of people with normal weight and people with overweight and obesity. A significant correlation was also observed between the concentrations of FGF-22 and FGF-23 and arthritis (p = 0.01; p = 0.02). FGF-2, FGF-19, FGF-22, and FGF-23 likely significantly impact diabetes and its complications. In the future, they could serve as biomarkers for diabetic complications, aiding in diagnosis, patient monitoring, and even predicting potential complications for individuals. However, more research in this area is necessary.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Fibroblast Growth FactorsDiabetes Mellitus, Type 1Diabetes ComplicationsHumansMaleFemaleAdultMiddle AgedBiomarkersAgedYoung AdultAdolescentFibroblast Growth Factor-23Aged, 80 and overFibroblast Growth Factor 2Case-Control Studies

Stichwörter der Autor:innen

FGF-19FGF-2FGF-22FGF-23diabetes type 1diabetes type 2diabetic complications

Substanzen

Fibroblast Growth FactorsBiomarkersFibroblast Growth Factor-23FGF23 protein, humanFibroblast Growth Factor 2FGF19 protein, human

Autor:innen und Institutionen

  • Department of Laboratory Medicine, Pomeranian Medical University of Szczecin, Powstancow Wielkopolskich 72, 70-111 Szczecin, Poland.
  • Cardiothoracic Surgery Clinic, Cardiac Rehabilitation Department, Pomeranian Medical University of Szczecin, Powstancow Wielkopolskich 72, 70-111 Szczecin, Poland.
  • Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University of Szczecin, Powstancow Wielkopolskich 72, 70-111 Szczecin, Poland.

ORCID-Profile: Elżbieta Cecerska-Heryć, Radosław Birger, Natalia Serwin, Barbara Dołęgowska

Förderung

  • Pomeranian Medical University

Zitieren

APA

Cecerska-Heryć, E., Michałów, J., Engwert, W., Marciniak, J., Birger, R., Serwin, N., Heryć, R., Polikowska, A., Goszka, M., Wiśniewska, M., & Dołęgowska, B. (2025). The Promising Role of Selected Fibroblast Growth Factors as Potential Markers of Complications in Type 1 and Type 2 Diabetes. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26178754

Vancouver

Cecerska-Heryć E, Michałów J, Engwert W, Marciniak J, Birger R, Serwin N, et al. The Promising Role of Selected Fibroblast Growth Factors as Potential Markers of Complications in Type 1 and Type 2 Diabetes. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26178754

BibTeX
@article{CecerskaHery2025,
  author = {Cecerska-Heryć, Elżbieta and Michałów, Jaśmina and Engwert, Weronika and Marciniak, Julia and Birger, Radosław and Serwin, Natalia and Heryć, Rafał and Polikowska, Aleksandra and Goszka, Małgorzata and Wiśniewska, Magda and Dołęgowska, Barbara},
  title = {The Promising Role of Selected Fibroblast Growth Factors as Potential Markers of Complications in Type 1 and Type 2 Diabetes},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26178754}
}
Kostenlos starten →